FDA's inconsistent decisions frustrate rare disease advocates

FDA decisions on rare disease treatments are causing frustration among advocates and families. Regenxbio's gene therapy for Hunter Syndrome was rejected, requiring more data, potentially delaying approval for years. This follows other rejections or reversals of cell and gene therapies for rare diseases. Advocates fear the FDA may be moving away from a previously promised flexible approach to approving treatments for these often fatal conditions.